These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 17541560)
1. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Mancini F; Naldi M; Cavrini V; Andrisano V Anal Bioanal Chem; 2007 Jul; 388(5-6):1175-83. PubMed ID: 17541560 [TBL] [Abstract][Full Text] [Related]
2. Inkjet printing-based β-secretase fluorescence resonance energy transfer (FRET) assay for screening of potential β-secretase inhibitors of Alzheimer's disease. Lee J; Samson AAS; Song JM Anal Chim Acta; 2018 Aug; 1022():89-95. PubMed ID: 29729742 [TBL] [Abstract][Full Text] [Related]
3. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133 [TBL] [Abstract][Full Text] [Related]
4. Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently. Fu H; Dou J; Li W; Cui W; Mak S; Hu Q; Luo J; Lam CS; Pang Y; Youdim MB; Han Y Eur J Pharmacol; 2009 Nov; 623(1-3):14-21. PubMed ID: 19765582 [TBL] [Abstract][Full Text] [Related]
5. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease. Semighini EP Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252 [TBL] [Abstract][Full Text] [Related]
6. Development and characterization of beta-secretase monolithic micro-immobilized enzyme reactor for on-line high-performance liquid chromatography studies. Mancini F; Naldi M; Cavrini V; Andrisano V J Chromatogr A; 2007 Dec; 1175(2):217-26. PubMed ID: 17991476 [TBL] [Abstract][Full Text] [Related]
7. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609 [TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS). Fernández-Bachiller MI; Horatscheck A; Lisurek M; Rademann J ChemMedChem; 2013 Jul; 8(7):1041-56. PubMed ID: 23757181 [TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors. Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238 [TBL] [Abstract][Full Text] [Related]
10. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. Hook VY; Reisine TD J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Zhu Y; Xiao K; Ma L; Xiong B; Fu Y; Yu H; Wang W; Wang X; Hu D; Peng H; Li J; Gong Q; Chai Q; Tang X; Zhang H; Li J; Shen J Bioorg Med Chem; 2009 Feb; 17(4):1600-13. PubMed ID: 19162488 [TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0. Saric A; Brügge Lz; Müller-Pompalla D; Rysiok T; Ousson S; Permanne B; Quattropani A; Busch M; Beher D; Hussain I J Biomol Screen; 2013 Mar; 18(3):277-85. PubMed ID: 23023105 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and cell-based assays for characterization of BACE-1 inhibitors. Pietrak BL; Crouthamel MC; Tugusheva K; Lineberger JE; Xu M; DiMuzio JM; Steele T; Espeseth AS; Stachel SJ; Coburn CA; Graham SL; Vacca JP; Shi XP; Simon AJ; Hazuda DJ; Lai MT Anal Biochem; 2005 Jul; 342(1):144-51. PubMed ID: 15958191 [TBL] [Abstract][Full Text] [Related]
14. Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Hook V; Schechter I; Demuth HU; Hook G Biol Chem; 2008 Aug; 389(8):993-1006. PubMed ID: 18979625 [TBL] [Abstract][Full Text] [Related]
15. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937 [TBL] [Abstract][Full Text] [Related]
16. Progress in the development of beta-secretase inhibitors for Alzheimer's disease. Albert JS Prog Med Chem; 2009; 48():133-61. PubMed ID: 21544959 [TBL] [Abstract][Full Text] [Related]
18. BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity. Evin G; Lessene G; Wilkins S Recent Pat CNS Drug Discov; 2011 May; 6(2):91-106. PubMed ID: 21585329 [TBL] [Abstract][Full Text] [Related]
19. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production. Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711 [TBL] [Abstract][Full Text] [Related]
20. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. John S; Thangapandian S; Sakkiah S; Lee KW BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]